Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Premature Ejaculation Medication

  • Author: Samuel G Deem, DO; Chief Editor: Edward David Kim, MD, FACS  more...
 
Updated: Mar 15, 2016
 

Medication Summary

No drug is specifically approved by the US Food and Drug Administration (FDA) for the treatment of premature (early) ejaculation. However, various agents have been safely and effectively used for this purpose. Selective serotonin reuptake inhibitors (SSRIs) and antidepressants with SSRI-like effects have been the most successful. Desensitizing creams containing local anesthetics can also be useful in some cases; though not FDA-approved, they are believed to be of at least some efficacy and carry minimal risk.

Premature ejaculation that relates to erectile dysfunction may resolve if the erectile difficulty is treated successfully. Drugs for the treatment of erectile dysfunction include sildenafil, vardenafil, tadalafil, alprostadil, and, possibly, an SSRI (if depression is causing the erectile dysfunction).

Next

Selective Serotonin Reuptake Inhibitors

Class Summary

The mechanism of action of SSRIs is linked to their inhibition of neuronal uptake of serotonin (5-HT) in the central nervous system (CNS).

Various animal studies suggest that SSRIs have weak effects on norepinephrine and dopamine neuronal reuptake. They do not antagonize adrenergic (eg, alpha1 -adrenergic, alpha2 -adrenergic, or beta-adrenergic), cholinergic, GABAergic, dopaminergic, histaminergic, serotonergic (5-HT1A, 5-HT1B, or 5-HT2), or benzodiazepine receptors; therefore, they have fewer adverse anticholinergic effects than tricyclic antidepressants (TCAs) do.

Adverse effects of long-term SSRI use are a significant concern and should be considered by both the physician and the patient. These adverse effects include psychiatric and neurologic sequelae, dermatologic reactions, anticholinergic effects, fluctuation in body weight, cognitive impairment, drug interactions, and sexual side effects other than delayed ejaculation (eg, erectile dysfunction or loss of libido.

Paroxetine (Paxil, Pexeva)

 

Paroxetine is a potent SSRI used to treat premature ejaculation. Improvement may not be evident until at least 3 weeks after the initiation of treatment. If there is no beneficial effect on premature ejaculation after 6 weeks or if adverse effects become troublesome, it should be discontinued in favor of an alternative treatment.

Sertraline (Zoloft)

 

Sertraline is a potent SSRI used to treat premature ejaculation. Improvement may not be evident until at least 3 weeks after the initiation of treatment. If there is no beneficial effect on premature ejaculation after 6 weeks or if adverse effects become troublesome, it should be discontinued in favor of an alternative treatment.

Citalopram (Celexa)

 

Citalopram is a potent SSRI used to treat premature ejaculation. Improvement may not be evident until at least 3 weeks after the initiation of treatment. If there is no beneficial effect on premature ejaculation after 6 weeks or if adverse effects become troublesome, it should be discontinued in favor of an alternative treatment.

Fluoxetine (Prozac)

 

Fluoxetine is a potent SSRI used to treat premature ejaculation. Improvement may not be evident until at least 3 weeks after the initiation of treatment. If there is no beneficial effect on premature ejaculation after 6 weeks or if adverse effects become troublesome, it should be discontinued in favor of an alternative treatment.

Previous
Next

Tricyclic antidepressants

Class Summary

Drugs with SSRI-like side effects (eg, delaying sexual climax), such as certain TCAs, can be used to treat premature ejaculation. The TCA most studied for treatment of premature ejaculation is clomipramine, which may be more effective than many SSRIs for this purpose.

Clomipramine (Anafranil)

 

Clomipramine inhibits the membrane pump mechanism responsible for uptake of norepinephrine and serotonin in adrenergic and serotonergic neurons. These actions are believed to be responsible for its antidepressant activity. Inhibition of serotonin probably gives rise to the SSRI-like activity that produces side effects (eg, inhibition of ejaculation).

Previous
Next

Topical anesthetic agents

Class Summary

Topical anesthetics may reduce penile sensitivity and excitability and delay ejaculation. Topical anesthetic cream is probably the lowest-risk medication that can be used for premature ejaculation; it has no adverse systemic effects, in the absence of prior hypersensitivity to the medication on the part of the patient or his partner. As a rule, there is no contraindication for combined therapy with topical anesthetics, antidepressants, and behavioral therapy.

Lidocaine 2.5% and prilocaine 2.5% (EMLA)

 

Lidocaine and prilocaine are amide-type local anesthetic agents. Both agents stabilize neuronal membranes by inhibiting the flow of certain ions required for the initiation and conduction of nerve impulses, thus producing local anesthesia. Lidocaine and prilocaine are applied to intact skin under an occlusive dressing, providing dermal analgesia. The effectiveness of this approach when it is applied to the penis is unproved; an occlusive dressing might also be difficult unless the penis is covered with a condom or cellophane.

Previous
Next

Phosphodiesterase Type 5 Inhibitors

Class Summary

In some studies, sildenafil and other phosphodiesterase type 5 (PDE5) inhibitors in combination with SSRIs has yield better results in treating premature ejaculation than SSRIs alone. The mechanism of this effect is unknown. Regardless of the mechanism, PDE5 inhibitors are safe and effective treatment adjuncts for premature ejaculation if not otherwise contraindicated. The only PDE5 inhibitors studied to any degree in this setting are sildenafil and tadalafil; vardenafil may also work, but more data are needed.

Sildenafil (Viagra)

 

Sildenafil is FDA-approved for the treatment of erectile dysfunction but not specifically for the treatment of premature ejaculation. If both conditions are present, sildenafil may help them both. Sildenafil in combination with an SSRI-type drug alleviates premature ejaculation better than an SSRI-type drug alone, as measured by prolongation of intravaginal ejaculatory latency time (IELT). More drug-related adverse events may occur because 2 medications are being used rather than just 1.

Tadalafil (Cialis)

 

Tadalafil is FDA-approved for the treatment of erectile dysfunction but not specifically for the treatment of premature ejaculation. Studies suggest that it may improve both conditions concurrently. Tadalafil in combination with an SSRI-type drug alleviates premature ejaculation better than an SSRI-type drug alone, as measured by prolongation of IELT. More drug-related adverse events may occur because 2 medications are being used rather than just 1.

Inhibition of PDE5 increases cyclic guanosine monophosphate (cGMP) activity, which increases the vasodilatory effects of nitric oxide. Sexual stimulation is necessary to activate response. Increased sensitivity for erections may last 36 hours with intermittent dosing. For more frequent sexual activity (eg, twice weekly), a daily low-dose regimen may be recommended; men can attempt sexual activity at any time between daily doses. Tadalafil is available as 2.5-mg, 5-mg, 10-mg, and 20-mg tablets.

Previous
Next

Beta-adrenergic Blocker

Class Summary

Pindolol is a nonselective beta-adrenergic antagonist that has been shown to have 5-HT1A autoreceptor antagonist properties in the dorsal raphe nuclei. It is hypothesized that this 5-HT1A autoreceptor antagonism increases the synaptic content of 5-HT and subsequently potentiates the action of an SSRI medication. More studies are required before pindolol can be considered an ideal option for first- or second-line treatment of premature ejaculation.

Pindolol

 

Pindolol is a nonselective beta-adrenergic antagonist used in combination with paroxetine for premature ejaculation refractory to paroxetine alone. This is an off-label use of pindolol.

Previous
Next

Analgesic, Opioid

Class Summary

Tramadol is an analgesic with centrally acting opioid activity (weak μ-opioid effect) in addition to inhibition of reuptake of 5-HT and norepinephrine. It is hypothesized that the increased synaptic content of serotonin and norepinephrine at the level of the spinal cord and peripheral sensory nerves provides the mechanism for effective treatment of premature ejaculation.

Tramadol (Ultram, Rybix ODT, ConZip, Ryzolt)

 

Tramadol is a centrally acting opioid analgesic that exerts its effect by combining opioid receptor activation with inhibition of norepinephrine and serotonin reuptake. If there is no beneficial effect on premature ejaculation after 6 weeks or if adverse effects become troublesome, it should be discontinued in favor of an alternative treatment. Treatment of premature ejaculation is an off-label use of tramadol.

Previous
 
Contributor Information and Disclosures
Author

Samuel G Deem, DO Faculty, Department of Urology, Charleston Area Medical Center

Samuel G Deem, DO is a member of the following medical societies: American College of Surgeons, American Osteopathic Association, American Urological Association, Endourological Society, Society of Urologic Oncology, American Society of Clinical Oncology, American College of Osteopathic Surgeons

Disclosure: Nothing to disclose.

Chief Editor

Edward David Kim, MD, FACS Professor of Surgery, Division of Urology, University of Tennessee Graduate School of Medicine; Consulting Staff, University of Tennessee Medical Center

Edward David Kim, MD, FACS is a member of the following medical societies: American College of Surgeons, Tennessee Medical Association, Sexual Medicine Society of North America, American Society for Reproductive Medicine, American Society of Andrology, American Urological Association

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Repros.

Acknowledgements

Aaron Benson, MD Staff Physician, Department of Surgery, Division of Urology, Southern Illinois University School of Medicine

Aaron Benson, MD is a member of the following medical societies: American Medical Association, American Urological Association, and Illinois State Medical Society

Disclosure: Nothing to disclose. Leonard Gabriel Gomella, MD, FACS The Bernard W Godwin Professor of Prostate Cancer Chairman, Department of Urology, Associate Director of Clinical Affairs, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Leonard Gabriel Gomella, MD, FACS is a member of the following medical societies: American Association for Cancer Research, American College of Surgeons, American Medical Association, American Society for Laser Medicine and Surgery, American Urological Association, Sigma Xi, Society for Basic Urologic Research, Society of University Urologists, and Society of Urologic Oncology

Disclosure: GSK Consulting fee Consulting; Astra Zeneca Honoraria Speaking and teaching; Watson Pharmaceuticals Consulting fee Consulting

Milton Lakin, MD Head, Section of Medical Urology, Urological Institute, Cleveland Clinic

Milton Lakin, MD is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine, American Diabetes Association, American Medical Association, and American Urological Association

Disclosure: Nothing to disclose.

Mark Jeffrey Noble, MD Consulting Staff, Urologic Institute, Cleveland Clinic Foundation

Mark Jeffrey Noble, MD is a member of the following medical societies: American College of Surgeons, American Medical Association, American Urological Association, Kansas Medical Society, Sigma Xi, Society of University Urologists, and Southwest Oncology Group

Disclosure: Nothing to disclose.

Loren B Ost, MD Associate Professor, Department of Surgery, Southern Illinois University School of Medicine; Urologist, SIU Physicians and Surgeons

Loren B Ost, MD is a member of the following medical societies: American Urological Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References
  1. Masters WH, Johnson VE. Premature ejaculation. Human Sexual Inadequacy. Boston, Mass: Little Brown & Company; 1970. 92-115.

  2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. Washington, DC: APA Press; 2013.

  3. Buvat J. Pathophysiology of premature ejaculation. J Sex Med. 2011 Oct. 8 Suppl 4:316-27. [Medline].

  4. Peeters M, Giuliano F. Central neurophysiology and dopanergic control of ejaculation. Neurosci Biobehav Rev. 2008. 32(3):438-53. [Medline].

  5. Corona G, Jannini EA, Mannucci E et al. Different testosterone levels are associated with ejaculatory dysfunction. J Sex Med. August 2008. 8:1991-8. [Medline].

  6. Yao B, Li XY, Zhao ZM et al. Semen biochemical markers and their significance in the patients with premature ejaculation. Zhonghua Nan Ke Xue. December 2007. 13(12):1084-6. [Medline].

  7. Corona G, Mannucci E, Jannini EA, Lotti F, Ricca V, Monami M, et al. Hypoprolactinemia: A New Clinical Syndrome in Patients with Sexual Dysfunction. J Sex Med. 2009 Feb 10. [Medline].

  8. Patrick DL, Althof SE, Pryor JL, Rosen R, Rowland DL, Ho KF, et al. Premature ejaculation: an observational study of men and their partners. J Sex Med. 2005 May. 2(3):358-67. [Medline].

  9. Patrick DL, Rowland D, Rothman M. Interrelationships among measures of premature ejaculation: the central role of perceived control. J Sex Med. 2007 May. 4(3):780-8. [Medline].

  10. Verma KK, Khaitan BK, Singh OP. The frequency of sexual dysfunctions in patients attending a sex therapy clinic in north India. Arch Sex Behav. 1998 Jun. 27(3):309-14. [Medline].

  11. Giuliano F, Patrick DL, Porst H, La Pera G, Kokoszka A, Merchant S, et al. Premature ejaculation: results from a five-country European observational study. Eur Urol. 2008 May. 53(5):1048-57. [Medline].

  12. Frewen A, Rapee RM, Bowden P, Lagios K. Regional differences in men attending a sexual health clinic in Sydney for premature ejaculation. J Sex Med. 2007 Nov. 4(6):1733-8. [Medline].

  13. Mohee A, Eardley I. Medical therapy for premature ejaculation. Ther Adv Urol. 2011 Oct. 3(5):211-22. [Medline]. [Full Text].

  14. Kilic S, Ergin, H, Baydinc YC. Venlafaxine extended release for the treatment of patients with premature ejaculation: a pilot, single-blind, placebo-controlled, fixed-dose crossover study on short-term administration of an antidepressant drug. Int J Androl. 2005. 28:47. [Medline].

  15. Porst H. An overview of pharmacotherapy in premature ejaculation. J Sex Med. 2011 Oct. 8 Suppl 4:335-41. [Medline].

  16. Choi HK, Jung GW, Moon KH, et al. Clinical study of SS-cream in patients with lifelong premature ejaculation. Urology. 2000 Feb. 55(2):257-61. [Medline].

  17. Xin ZC, Choi YD, Seong DH, Choi HK. Sensory evoked potential and effect of SS-cream in premature ejaculation. Yonsei Med J. 1995 Nov. 36(5):397-401. [Medline].

  18. Busato W, Galindo CC. Topical anaesthetic use for treating premature ejaculation: a double-blind, randomized, placebo-controlled study. BJU Int. 2004 May. 93(7):1018-21. [Medline].

  19. Henry R, Morales A. Topical lidocaine-prilocaine spray for the treatment of premature ejaculation: a proof of concept study. Int J Impot Res. 2003 Aug. 15(4):277-81. [Medline].

  20. Berkovitch M, Keresteci AG, Koren G. Efficacy of prilocaine-lidocaine cream in the treatment of premature ejaculation. J Urol. 1995 Oct. 154(4):1360-1. [Medline].

  21. Pu C, Yang L, Liu L, Yuan H, Wei Q, Han P. Topical anesthetic agents for premature ejaculation: a systematic review and meta-analysis. Urology. 2013 Apr. 81(4):799-804. [Medline].

  22. Colpi GM, Fanciullacci F, Aydos K, Grugnetti C. Effectiveness mechanism of chlomipramine by neurophysiological tests in subjects with true premature ejaculation. Andrologia. 1991 Jan-Feb. 23(1):45-7. [Medline].

  23. Girgis SM, El-Haggar S, El-Hermouzy S. A double-blind trial of clomipramine in premature ejaculation. Andrologia. 1982 Jul-Aug. 14(4):364-8. [Medline].

  24. Goodman RE. An assessment of clomipramine (Anafranil) in the treatment of premature ejaculation. J Int Med Res. 1980. 8 Suppl 3:53-9. [Medline].

  25. Haensel SM, Rowland DL, Kallan KT. Clomipramine and sexual function in men with premature ejaculation and controls. J Urol. 1996 Oct. 156(4):1310-5. [Medline].

  26. Kim SC, Seo KK. Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. J Urol. 1998 Feb. 159(2):425-7. [Medline].

  27. Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet. 2006 Sep 9. 368(9539):929-37. [Medline].

  28. Safarinejad MR. Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clin Neuropharmacol. 2006 Sep-Oct. 29(5):243-52. [Medline].

  29. Safarinejad MR. Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology. 2008 May. 33(6):1259-65. [Medline].

  30. McMahon CG, Giuliano F, Dean J, Hellstrom WJ, Bull S, Tesfaye F, et al. Efficacy and Safety of Dapoxetine in Men with Premature Ejaculation and Concomitant Erectile Dysfunction Treated with a Phosphodiesterase Type 5 Inhibitor: Randomized, Placebo-Controlled, Phase III Study. J Sex Med. 2013 Jul 11. [Medline].

  31. Giuliano F, Hellstrom WJ. The pharmacological treatment of premature ejaculation. BJU Int. 2008 Sep. 102(6):668-75. [Medline].

  32. Black K, Shea C, Dursun S, Kutcher S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci. 2000 May. 25(3):255-61. [Medline].

  33. Abdel-Hamid IA. Phosphodiesterase 5 inhibitors in rapid ejaculation: potential use and possible mechanisms of action. Drugs. 2004. 64(1):13-26. [Medline].

  34. Mattos RM, Marmo Lucon A, Srougi M. Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urol Int. 2008. 80(2):162-5. [Medline].

  35. Chen J, Keren-Paz G, Bar-Yosef Y, Matzkin H. The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data. Eur Urol. 2007 Nov. 52(5):1331-9. [Medline].

  36. Blier P, Bergeron R, de Montigny C. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response. Neuropsychopharmacology. 1997 May. 16(5):333-8. [Medline].

  37. Safarinejad MR. Once-daily high-dose pindolol for paroxetine-refractory premature ejaculation: a double-blind, placebo-controlled and randomized study. J Clin Psychopharmacol. 2008 Feb. 28(1):39-44. [Medline].

  38. Safarinejad MR, Hosseini SY. Safety and efficacy of tramadol in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. J Clin Psychopharmacol. 2006 Feb. 26(1):27-31. [Medline].

  39. Salem EA, Wilson SK, Bissada NK, Delk JR, Hellstrom WJ, Cleves MA. Tramadol HCL has promise in on-demand use to treat premature ejaculation. J Sex Med. 2008 Jan. 5(1):188-93. [Medline].

  40. Yang L, Qian S, Liu H, Liu L, Pu C, Han P, et al. Role of Tramadol in Premature Ejaculation: A Systematic Review and Meta-Analysis. Urol Int. 2013 Jun 6. [Medline].

  41. David Prologo J, Snyder LL, Cherullo E, Passalacqua M, Pirasteh A, Corn D. Percutaneous CT-guided Cryoablation of the Dorsal Penile Nerve for Treatment of Symptomatic Premature Ejaculation. J Vasc Interv Radiol. 2013 Feb. 24(2):214-9. [Medline].

  42. Lee SW, Lee JH, Sung HH, Park HJ, Park JK, Choi SK, et al. The prevalence of premature ejaculation and its clinical characteristics in Korean men according to different definitions. Int J Impot Res. 2013 Jan. 25 (1):12-7. [Medline].

  43. Corona G, Rastrelli G, Limoncin E, Sforza A, Jannini EA, Maggi M. Interplay Between Premature Ejaculation and Erectile Dysfunction: A Systematic Review and Meta-Analysis. J Sex Med. 2015 Dec. 12 (12):2291-300. [Medline].

  44. Lee JH, Lee SW. Relationship between premature ejaculation and chronic prostatitis/chronic pelvic pain syndrome. J Sex Med. 2015 Mar. 12 (3):697-704. [Medline].

  45. Serefoglu EC, McMahon CG, Waldinger MD, Althof SE, Shindel A, Adaikan G, et al. An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. J Sex Med. 2014 Jun. 11 (6):1423-41. [Medline].

  46. [Guideline] Althof SE, McMahon CG, Waldinger MD, Serefoglu EC, Shindel AW, Adaikan PG, et al. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). J Sex Med. 2014 Jun. 11 (6):1392-422. [Medline]. [Full Text].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.